

PT	mat_peptide	61..1560
FT	/*tag= c	
FT	/product= "mature zcytor19"	
XX		
PN	NO200244209-A2.	
XX		
FD	06-JUN-2002.	
XX		
PE	28-NOV-2001; 2001WO-US44808.	
XX		
PR	28-NOV-2000; 2000US-253561P.	
PR	07-FEB-2001; 2001US-267211P.	
XX		
PA	(ZYMO) ZYMOGENETICS INC.	
XX		
FI	Presnell SR, Xu W, Novak TE, Whitmore TE, Grant FJ;	
XX		
DR	WPI; 2002-527700/56.	
DR	P-PSDB; ABB81643.	
XX		
PT	Novel zcytor19 polypeptides and polynucleotides useful for stimulating	
PT	immune responses in animals for producing antibodies, and for creating	
PT	autoimmune diseases, leukemia and asthma -	
XX		
PS	Claim 2; Page 174-177; 200pp; English.	

Db	1376	CTGGGTCCTGGGGAGACCCCAAGTTCTCTTCACACACTGACCTTCTGCTGGAAAGAC	1437
Qy	1316	CCTGAGGAGGAAAGAGAGGCGGAGGGAATCAGAAATTGAGGACAGGAGTCGGGCACTGG	1375
Db	1438	CTTGAGGAGGAAAGAGAGGCGGAGGGAATCAGAAATTGAGGACAGGAGTCGGGCACTGG	1497
Qy	1376	GGGGCTGAGAGCACCCAGAGGAGCCAGGAGGACAGGGGCGGAGCATTTGGGGCATTTGATGGCC	1435
Db	1498	GGGGCTGAGAGCACCCAGAGGAGCCAGGAGGACAGGGGCGGAGCATTTGGGGCATTTGATGGCC	1557
Qy	1436	AGGTGA 1441	
Db	1558	AGGTGA 1563	
RESULT 2 :			
ADD50487	ADD50487	standard; cDNA; 1563 BP.	
XX	XX	ADD50487;	
XX	AC		
XX	XX	24-MAR-2003 (first entry)	
DT	DE		
XX	XX	Human zcytor19 receptor cDNA.	
XX	XX		
XX	XX	Human; leukaemia; carcinoma; acquired immune deficiency syndrome; AIDS;	
KW	KW	melanoma; Kaposi's sarcoma; multiple myeloma; non-Hodgkin's lymphoma;	
KW	KW	hepatitis; infection; myocarditis; blood vessel formation; gene therapy;	
KW	KW	growth regulation; developmental process; immunotherapy; zcytor19; gene;	
XX	XX	receptor; ss.	
XX	OS		
XX	XX	Homo sapiens.	
Key	Key	Location/Qualifiers	
FT	FT	1..1563	
FT	FT	/*tag= a	
FT	FT	/product= "Human zcytor19 receptor"	
FT	FT	1..60	
FT	FT	/*tag= b	
FT	FT	61..1560	
FT	FT	/*tag= c	
FT	FT	/product= "Mature human zcytor19 receptor"	
XX	XX		
XX	XX	MO200286087-AZ.	
XX	PD	31-OCT-2002.	
XX	XX		
XX	XX	19-APR-2002; 2002MO-US12887.	
XX	XX		
XX	XX	20-APR-2001; 2001US-285408P.	
XX	XX	20-APR-2001; 2001US-285424P.	
XX	XX	25-APR-2001; 2001US-286482P.	
XX	XX	29-JUN-2001; 2001US-0895834.	
XX	XX	22-OCT-2001; 2001US-341050P.	
XX	XX	22-OCT-2001; 2001US-341105P.	
XX	XX		
XX	XX	(Zymo) ZYMOGENETICS INC.	
XX	XX		
XX	XX	Sheppard PO, Fox BA, Klucher KM, Taft DW, Kindsvogel WR,	
XX	XX	WPI; 2003-093122/08.	
XX	XX	P-PSDB; AAB32768.	
XX	XX		
XX	XX	New zcyto20, zcyto21, zcyto22, zcyto24 and zcyto25 polypeptides and	
XX	XX	polynucleotides useful for treating leukemia, carcinoma, malignant	
XX	XX	melanoma, AIDS-related Kaposi's sarcoma, myeloma, non-Hodgkin's	
XX	XX	lymphoma, hepatitis and infections	
XX	XX		
XX	XX	Example 30; Page 147-148; 160pp; English.	
XX	XX		
XX	XX	The invention relates to zcyto20, zcyto21, zcyto22, zcyto24 and zcyto25	
XX	XX	polypeptides and polynucleotides. Sequences of the invention are useful	
XX	XX	for treating hairy cell leukemia, renal cell or basal cell carcinoma,	

[illegible]


```

Db      181 AGCTCTCCACCCGTTAGACGGTGGCGGAGAGTGGAAAGATGTGCGGGAAACAAAGAGCTG 240
Qy      247 CTATGTTCTATGATGTGCTTGAGAAACGAGACTGTACAAAGTTCAAGGAGCGCTG 306
Db      241 CTATGTTCTATGATGTGCTTGAGAAACGAGACTGTACAAAGTTCAAGGAGCGCTG 300
Qy      307 CGAGCGGTTCTCCAGCTCCAGTCCCGCTGGGTGAGTCCGAAATACCTGATTAACCT 366
Db      301 CGAGCGGTTCTCCAGCTCCAGTCCCGCTGGGTGAGTCCGAAATACCTGATTAACCT 360
Qy      367 TTGTAAGTGAAGCGCGCGCCCACTGTCTGATGTCTACCCAGACGAGAGAGATCTGAGT 426
Db      361 TTGTAAGTGAAGCGCGCGCCCACTGTCTGATGTCTACCCAGACGAGAGAGATCTGAGT 420
Qy      427 GCCAATGCCAGTACGAGCTGCGCCCTGATGAGCGCCCACTGATGATGATGAGT 486
Db      421 GCCAATGCCAGTACGAGCTGCGCCCTGATGAGCGCCCACTGATGATGATGAGT 480
Qy      487 GCATTTCTGAGAGAGAGGGGGCCGGAACCAAGACCTTATTTCAATCTCCCAATGCGAG 546
Db      481 GCATTTCTGAGAGAGAGGGGGCCGGAACCAAGACCTTATTTCAATCTCCCAATGCGAG 540
Qy      547 CCAATCCAGATCACTCTCCAGCGAGCTGCGAGAGACCACTGCTCAGTCCAGAAAC 606
Db      541 CCAATCCAGATCACTCTCCAGCGAGCTGCGAGAGACCACTGCTCAGTCCAGAAAC 600
Qy      607 ATCTACACGTTTCAAGTGTCCGAAATATACAGCAAGTTCTTAAAGCGACCTGTTGCTG 666
Db      601 ATCTACACGTTTCAAGTGTCCGAAATATACAGCAAGTTCTTAAAGCGACCTGTTGCTG 660
Qy      667 GAGGTCCAGAGACTTTTCTGAGCACAC-----A 694
Db      661 GAGGTCCAGAGACTTTTCTGAGCACAC-----A 694
Qy      695 CACCTGTGCAACCTTTGAGCGCGAGAGACCAAGTCCGTAATGATCTGTTCTCTG 754
Db      721 GTATTTCCGAGAGGGGTGTGATCTGAGAAACCTCATGAGAGACCTGTTGAGCGG 780
Qy      755 CCCCAGAA-----AGGACTGACAGAGGGGTCAAGGCGGAGCGCTCAGTCAAG 802
Db      781 GCAAGAGTGCACAGGCGCCCTGAGACCTGACAGAGGGGTCAAGGCGGAGCGCTCAGTCAAG 840
Qy      803 GCCCAGCGACCCCAAGACAGATGAGAAAGAGACCTTCAAGAGAGAGAGAGAG 862
Db      841 GCCCAGCGACCCCAAGACAGATGAGAAAGAGACCTTCAAGAGAGAGAGAGAG 900
Qy      863 GATGAGAGAGACAGAAAGTGGCTCAAGCTTCCAGCGCTTCAATGACCACTTCTTC 922
Db      901 GATGAGAGAGACAGAAAGTGGCTCAAGCTTCCAGCGCTTCAATGACCACTTCTTC 960
Qy      923 CTGGGGCAAGAGCAAGGCTCAGGGCACTCGAGGCT?TGTGTGGGTGAGCTCAGGG 982
Db      961 CTGGGGCAAGAGCAAGGCTCAGGGCACTCGAGGCT---TGTGTGGGTGAGCTCAGGG 1017
Qy      983 AGGCGCAGGCTCTCTGCTCCAGAGAGCTCTCTGCTGGGATTTCTTCAAGACGA 1042
Db      1018 AGGCGCAGGCTCTCTGCTCCAGAGAGCTCTCTGCTGGGATTTCTTCAAGACGA 1077
Qy      1043 AGCTGGGCGAGCACTGTGACTCTCTCTGAGACAGGGCTGGGTCTCTGAGCTAATTTGCT 1102
Db      1078 AGCTGGGCGAGCACTGTGACTCTCTCTGAGACAGGGCTGGGTCTCTGAGCTAATTTGCT 1137
Qy      1103 GAGAGAGGGGCGAGGCGGCGGAGTGGGAGTGGGAGCCAAAGATCTCTCCACACACT 1162
Db      1138 GAGAGAGGGGCGAGGCGGCGGAGTGGGAGTGGGAGCCAAAGATCTCTCCACACACT 1197
Qy      1163 GAATTTCTCAAGAGCTCGGGTTTCTCTGAGAGAGCTCCCAAGAGATACTTCTCTG 1222
Db      1198 GAATTTCTCAAGAGCTCGGGTTTCTCTGAGAGAGCTCCCAAGAGATACTTCTCTG 1257
Qy      1223 GCCACTGTGGGCACTTACCAAGAGCGAATCTGTGCTCTGGGGGAGACCCCAAGTTCT 1282
Db      1258 GCCACTGTGGGCACTTACCAAGAGCGAATCTGTGCTCTGGGGGAGACCCCAAGTTCT 1317

```

```

Qy      1283 CTTGAGACATGACCTTTCTGTGGGAAAGAGAGCGCTTGAAGAGAAAGAGAGCGAGGAA 1342
Db      1318 CTTGAGACATGACCTTTCTGTGGGAAAGAGAGCGCTTGAAGAGAAAGAGAGCGAGGAA 1377
Qy      1343 TCAGAAATTGAGACAGAGATGCGGGGAGCTGGGGGCTGAGAGCAACCAAGAGACCGAG 1402
Db      1378 TCAGAAATTGAGACAGAGATGCGGGGAGCTGGGGGCTGAGAGCAACCAAGAGACCGAG 1437
Qy      1403 GACAGGGGCGCGACATTGGGGCAATTACATGAGCGAGTGA 1441
Db      1438 GACAGGGGCGCGACATTGGGGCAATTACATGAGCGAGTGA 1476

RESULT 4
AAB50485
ID AAB50485 standard; cDNA, 1476 BP.
XX
AC AAB50485;
XX
DT 24-MAR-2003 (first entry)
XX
DE Human zcytor19 receptor variant cDNA.
XX
KW Human; leukemia; carcinoma; acquired immune deficiency syndrome; AIDS;
KW hepatitis; infection; myocarditis; blood vessel formation; gene therapy;
KW growth regulation; developmental process; immunotherapy; zcytor19; gene;
KW receptor; variant; ss.
XX
OS Homo sapiens.
XX
FH Key 1 Location/Qualifiers
FT CDS 1..1476
FT     /tag= a
FT     /product= "Human zcytor19 receptor variant"
FT     /tag= b
FT     /tag= c
FT     /tag= C
FT     /product= "Mature human zcytor19 receptor variant"
XX
PN M0200286087-A2.
XX
PD 31-OCT-2002.
XX
PF 19-APR-2002; 2002M0-US12887.
XX
PR 20-APR-2001; 2001US-285408P.
XX
PR 20-APR-2001; 2001US-285424P.
XX
PR 25-APR-2001; 2001US-286482P.
XX
PR 29-JUN-2001; 2001US-0895834.
XX
PR 22-OCT-2001; 2001US-341050P.
XX
PR 22-OCT-2001; 2001US-341105P.
XX
PA (ZYMO ) ZYMOGENETICS INC.
XX
PI Sheppard PO, Fox BA, Klucher KM, Taft DW, Kindvogel WR;
PI WPI; 2003-093122/08.
XX
P-PSDB; AAB32766.
XX
PT New zcyto20, zcyto21, zcyto22, zcyto24 and zcyto25 polypeptides and
PT polynucleotides useful for treating leukemia, carcinoma, malignant
PT melanoma, AIDS-related Kaposi's sarcoma, myeloma, non-Hodgkin's
PT lymphoma, hepatitis and infections
XX
PS Example 18; Page 136-139; 160pp; English.
XX
CC The invention relates to zcyto20, zcyto21, zcyto22, zcyto24 and zcyto25
CC polypeptides and polynucleotides. Sequences of the invention are useful
CC for treating hairy cell leukemia, renal cell or basal cell carcinoma,
CC malignant melanoma, AIDS-related Kaposi's sarcoma, multiple myeloma,

```


XX (Zymo) ZYMOGENETICS INC.
 XX Presnell SR, Xu W, Novak JE, Whitmore TE, Grant FJ;
 XX WPI; 2002-527700/56.
 XX Novel zcytoris polypeptides and polynucleotides useful for stimulating
 PT immune responses in animals for producing antibodies, and for treating
 PT autoimmune diseases, leukemia and asthma -
 XX Disclosure; Page 165-166; 200pp; English.
 XX The present invention describes an isolated human zcytoris protein (1),
 CC and truncated zcytoris proteins. (1) has immunosuppressive, cytostatic,
 CC antineoplastic, antarthritic, neuroprotective, anti-HIV and haemostatic,
 CC antidiabetic, nephroprotective, dermatological, anti-HIV and haemostatic
 CC activities, and can be used in vaccines. (1) or an antibody binding (1)
 CC can be used for suppressing the immune system for reducing rejection of
 CC tissue or organ transplants and grafts and for treating T-cell specific
 CC leukemias or lymphomas and autoimmune diseases including rheumatoid
 CC arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel
 CC disease and Crohn's disease. The antibodies can also be used for treating
 CC immunologic renal diseases, glomerulonephritis, mesangiolipidiferative
 CC disease, chronic lymphocytic leukemia, secondary glomerulonephritis or
 CC vasculitis associated with lupus, polyarteritis, scleroderma, HIV-related
 CC diseases, amyloidosis and hemolytic uremic syndrome. (1) and the
 CC antibodies can also be used for renal or urological neoplasms and
 CC multiple myelomas, ascites, bronchitis, emphysema and other chronic
 CC airway diseases. Human zcytoris is located to chromosome 1, more
 CC specifically to chromosome 1p36.11. The present sequence represents a
 CC degenerate nucleotide sequence encoding a human zcytoris protein from
 CC the present invention.
 XX Sequence 1473 BP; 203 A; 195 C; 278 G; 164 T; 633 other;
 SO

Query Match 58.5%; Score 861.8; DB 24; Length 1473;
 Best Local Similarity 52.5%; Pred. No. 5.1e-215;
 Matches 775; Conservative 320; Mismatches 333; Indels 47; Gaps 3;

7 ATGGCGGGGCGCCAGCGCTGGGGGCCCCCTGCTCTGCTGCTGCGAGGCCCTCCAGAG 66
 1 ATGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 60
 67 AGCGCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 126
 61 MGNCCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 120
 127 CTGACATGCGCTCCAGAGGCTTGGGCAACCCCGAGAGTGAACCTATTGTCCTATGAG 186
 121 YTNACGTCGTCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 180
 187 AGCTCTCCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 246
 181 MSNCCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 240
 247 CTATGTCCTATGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCG 306
 241 YTNAGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTC 300
 307 CGAGCGGTCCTCCAGCTCCAGCTCCAGCTCCAGCTCCAGCTCCAGCTCCAGCTCCAGCT 366
 301 MGNCCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 360
 367 TTGAGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTC 426
 361 TTYGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTC 420
 427 GCGATGCGCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAG 486
 421 GCGATGCGCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAG 480
 487 GCAATTCGGAAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 546

DB 481 GCGATTCGGAAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 540
 QY 547 CCAGTCGAGTCACCTCTCCAGAGGCTGCGAGCAACCACTGCTCAGTGCAGAAC 606
 DB 541 CCAGTCGAGTCACCTCTCCAGAGGCTGCGAGCAACCACTGCTCAGTGCAGAAC 600
 QY 607 ATCTACAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTC 666
 DB 601 ATCTACAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTC 660
 QY 667 GAGTCCGAGCACTTTCTGAGCAACACACCTGTCGCAACCTTCCAGCCAGC----- 721
 DB 661 GAGTCCGAGCACTTTCTGAGCAACACACCTGTCGCAACCTTCCAGCCAGC----- 720
 QY 722 -----AGACGAGTCGCGGAGTGAATGACTGCTGCTGCTGCTGCTGCTGCTGCTGCT 754
 DB 721 GTRATGCGCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 780
 QY 755 CCGCAAG-----GAACTGACAGAGGCGTCCAGGCGGCGGCGGCGGCGGCGGCGGCGG 802
 DB 781 GCGAATGTCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 840
 QY 803 GCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 862
 DB 841 GCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 900
 QY 863 GATGAGAGAGCAAGAGATGCGCTGAGCTTCCAGCCCTCAATTGAACCACTTCTTTC 922
 DB 901 GATGAGAGAGCAAGAGATGCGCTGAGCTTCCAGCCCTCAATTGAACCACTTCTTTC 960
 QY 923 CTGGGCGAAGAGCAAGAGCTCCAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 982
 DB 961 YTNAGCGAGAGCAAGAGCTCCAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1017
 QY 983 AGCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1042
 DB 1018 MGNCCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1077
 QY 1043 AGCTGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1102
 DB 1078 MSNTGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1137
 QY 1103 GAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1162
 DB 1138 GAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1197
 QY 1163 GAATTCGCAAGAGCTGCGGCTTCTGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCG 1222
 DB 1198 GAATTCGCAAGAGCTGCGGCTTCTGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCG 1257
 QY 1223 GCGACCTGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1282
 DB 1258 GCGACCTGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1317
 QY 1283 CTTCAGACCTGCTCTGCTGCGGAAAGCGCTGAGAGAGAGAGAGAGAGAGAGAGAGAG 1342
 DB 1318 YTNACGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTC 1377
 QY 1343 TCAGAAATGAGAGCAAGAGATGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1402
 DB 1378 MSNAGATGAGAGCAAGAGATGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1437
 QY 1403 GAGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1437
 DB 1438 GATGAG 1472

RESULT 6
 AB073085
 ID AB073085 standard; cDNA; 1560 BP.
 XX
 AC AB073085;

QY 607 ATCTACAGTTCAGTGTCCGAAATACAGCAAGTCTCTAGCCCACTGCTTCTGCTG 666
 DB 649 ATCTACAGTTCAGTGTCCGAAATACAGCAAGTCTCTAGCCCACTGCTTCTGCTG 708
 QY 667 GAGTCCCAAGACATTTCTGACCA 690
 DB 709 GAGTCCCAAGACATTTCTGACCA 732
 RESULT 8
 ABQ73089
 ID ABQ73089 standard; cDNA; 1922 BP.
 AC ABQ73089;
 XX
 DT 25-SEP-2002 (first entry)
 XX
 DE MBP and zcytor19 fusion protein encoding cDNA SEQ ID NO:32.
 XX
 KW Human; zcytor19; cytokine receptor; immunosuppressive; cytosolic;
 KW anti-rheumatic; anti-arthritic; neuroprotective; anti-inflammatory;
 KW antidiabetic; nephroprotective; dermatological; anti-HIV; haemostatic;
 KW vaccine; immune system; T-cell specific leukemia; lymphoma; lupus;
 KW autoimmune disease; rheumatoid arthritis; multiple sclerosis; HIV;
 KW diabetes mellitus; inflammatory bowel disease; Crohn's disease; asthma;
 KW immunologic renal disease; glomerulonephritis; vasculitis; polyarteritis;
 KW mesangiolipoferrative disease; chronic lymphocytic leukemia; bronchitis;
 KW secondary glomerulonephritis; scleroderma; amyloidosis; multiple myeloma;
 KW haemolytic uraemic syndrome; renal neoplasm; urological neoplasm;
 KW emphysema; chronic airway disease; chromosome 1; chromosome 1p36.11;
 KW gene; ss.
 XX
 OS Homo sapiens.
 XX Synthetic.
 XX
 FH Key Location/Qualifiers
 FT 123..1922
 FT CDS /*tag= a
 FT /product= "maltose binding protein (MBP) and human
 FT zcytor19 fusion protein"
 XX
 PN WO200244209-A2.
 XX
 PD 06-JUN-2002.
 XX
 PF 28-NOV-2001; 2001MO-US44808.
 XX
 PR 28-NOV-2000; 2000US-253561P.
 PR 07-FEB-2001; 2001US-267211P.
 XX
 PA (ZYMO) ZYMOGENETICS INC.
 XX
 PI Presnell SR, Xu W, Novak JE, Whitmore TE, Grant FU;
 DR WPI; 2002-527700/56.
 DR P-PSDB; ABB81646.
 XX
 PT Novel Zcytor19 polypeptides and polynucleotides useful for stimulating
 PT immune responses in animals for producing antibodies, and for treating
 PT autoimmune diseases, leukemia and asthma.
 XX
 PS Example 10; Page 189-193; 200pp; English.
 XX
 CC The present invention describes an isolated human zcytor19 protein (1),
 CC and truncated zcytor19 proteins. (1) has immunosuppressive, cytosolic,
 CC anti-rheumatic, anti-arthritic, neuroprotective, anti-inflammatory,
 CC antidiabetic, nephroprotective, dermatological, anti-HIV and haemostatic
 CC activities, and can be used in vaccine, (1) or an antibody binding (1)
 CC can be used for suppressing the immune system for reducing rejection of
 CC tissue or organ transplants and grafts and for treating T-cell specific
 CC leukemias or lymphomas and autoimmune diseases including rheumatoid
 CC arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel
 CC disease and Crohn's disease. The antibodies can also be used for treating

CC immunologic renal diseases, glomerulonephritis, mesangiolipoferrative
 CC disease, chronic lymphocytic leukemia, secondary glomerulonephritis or
 CC vasculitis associated with lupus, polyarteritis, scleroderma, HIV-related
 CC diseases, amyloidosis and haemolytic uraemic syndrome. (1) and the
 CC antibodies can also be used for renal or urological neoplasms and
 CC multiple myelomas, asthma, bronchitis, emphysema and other chronic
 CC airway diseases. Human zcytor19 is located to chromosome 1, more
 CC specifically to chromosome 1p36.11. The present sequence encodes a
 CC maltose binding protein (MBP) and human zcytor19 fusion protein from
 CC the present invention.
 XX
 SQ Sequence 1922 BP; 503 A; 517 C; 503 G; 399 T; 0 other;
 XX
 Query Match 41.5%; Score 611.6; DB 24; Length 1922;
 Best Local Similarity 97.0%; Pred. No. 1.4e-149;
 Matches 623; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
 QY 46 CTGCTGCAAGGCGCTCCAGGAGGCGCGCTGCGCCCTCCCAAGATGACCGTCTC 105
 DB 1266 CCGCTGTGTCGCGCTGATCCAGGCGCGCGCTGCGCCCTCCCAAGATGACCGTCTC 1325
 QY 106 TCCCAAGATTCAGGCTGATCCTGACATGAGCTCCAGGCTTGGCAACCCCAAGATG 165
 DB 1326 TCCCAAGATTCAGGCTGATCCTGACATGAGCTCCAGGCTTGGCAACCCCAAGATG 1385
 QY 166 ACTATTTTGTGGCTTATCAGAGCTTCCCAACCGTGAACGGTGGCCGAAGTGAAG 225
 DB 1386 ACTATTTTGTGGCTTATCAGAGCTTCCCAACCGTGAACGGTGGCCGAAGTGAAG 1445
 QY 226 TGTGCGGAGACCAAGAGCTGCTATGTTCTATGATGAGCTGAAGAAACAGACCTGAC 285
 DB 1446 TGTGCGGAGACCAAGAGCTGCTATGTTCTATGATGAGCTGAAGAAACAGACCTGAC 1505
 QY 286 AACAGTTTAAAGGAGACGGTGGCGGAGCGTTTCTCCCACTCCAGTCCCTGGTGGAG 345
 DB 1506 AACAGTTTAAAGGAGACGGTGGCGGAGCGTTTCTCCCACTCCAGTCCCTGGTGGAG 1565
 QY 346 TCCGAATACCTGATTAACCTTTTGAAGTGAAGCCGCGCCCACTGCTGCTGCTAC 405
 DB 1566 TCCGAATACCTGATTAACCTTTTGAAGTGAAGCCGCGCCCACTGCTGCTGCTAC 1625
 QY 406 CAGACGAGAGAGATCTGAGTGGCAATGCGACATGACAGTCCGCGCCCTGCAATGCCCA 465
 DB 1626 CAGACGAGAGAGATCTGAGTGGCAATGCGACATGACAGTCCGCGCCCTGCAATGCCCA 1685
 QY 466 CTGATCTGAAGTATGAGTGGCAATTTCTGAAGAGGGGGCCGGAACCAAGACCTATT 525
 DB 1686 CTGATCTGAAGTATGAGTGGCAATTTCTGAAGAGGGGGCCGGAACCAAGACCTATT 1745
 QY 526 CAGATCACTCCCAATGGCCAGAGTCCAGATCACTTCCAGCCAGCTGCCAGCAAC 585
 DB 1746 CAGATCACTCCCAATGGCCAGAGTCCAGATCACTTCCAGCCAGCTGCCAGCAAC 1805
 QY 586 CACTGCTTCATGTCGCAACCAATCTACAGTTCAGTGTCCGAATACAGCAAGTTCTCT 645
 DB 1806 CACTGCTTCATGTCGCAACCAATCTACAGTTCAGTGTCCGAATACAGCAAGTTCTCT 1865
 QY 646 AAGCCCACTGCTCTTGTGAGAGTCCCAAGACTTTTCTGG 687
 DB 1866 AAGCCCACTGCTCTTGTGAGAGTCCCAAGACTTTTCTGG 1907
 RESULT 9
 ABQ73079
 ID ABQ73079 standard; cDNA; 673 BP.
 AC ABQ73079;
 XX
 DT 25-SEP-2002 (first entry)
 XX
 DE Human truncated soluble zcytor19 encoding cDNA SEQ ID NO:20.
 XX
 KW Human; zcytor19; cytokine receptor; immunosuppressive; cytosolic;

OS	Homo sapiens.
XX	
FN	W0200244209-A2.
XX	
PD	06-JUN-2002.
XX	
PP	28-NOV-2001; 2001WO-US44808.
XX	
XX	28-NOV-2000; 2000US-253561P.
PR	07-FEB-2001; 2001US-267211P.
PR	
XX	
PA	(ZYMO) ZYMOGENETICS INC.
XX	
PI	Presnell SR, Xu W, Novak VB, Whitmore TB, Grant FJ;
DR	WPI; 2002-527700/56.
XX	
PT	Novel Zcytor15 polypeptides and polynucleotides useful for stimulating
XX	immune responses in animals for producing antibodies, and for treating
PT	autoimmune diseases, leukemia and asthma -

1. (a) $\frac{1}{2}$ (b) $\frac{1}{2}$ (c) $\frac{1}{2}$ (d) $\frac{1}{2}$ (e) $\frac{1}{2}$ (f) $\frac{1}{2}$ (g) $\frac{1}{2}$ (h) $\frac{1}{2}$ (i) $\frac{1}{2}$ (j) $\frac{1}{2}$ (k) $\frac{1}{2}$ (l) $\frac{1}{2}$ (m) $\frac{1}{2}$ (n) $\frac{1}{2}$ (o) $\frac{1}{2}$ (p) $\frac{1}{2}$ (q) $\frac{1}{2}$ (r) $\frac{1}{2}$ (s) $\frac{1}{2}$ (t) $\frac{1}{2}$ (u) $\frac{1}{2}$ (v) $\frac{1}{2}$ (w) $\frac{1}{2}$ (x) $\frac{1}{2}$ (y) $\frac{1}{2}$ (z) $\frac{1}{2}$

RESULT 13
AAFC4460
ID AAFC4460 standard; cDNA, 374 BP.
XX
AC AAFC4460;
XX

QY 511 AACAGAGCCCTATTTCAGTCACTCCCAATGCGAGCCAGTCCAGATCACTCTCCAGCCA 570
 DB 207 AACAGAGCCCTATTTCAGTCACTCCCAATGCGAGCCAGTCCAGATCACTCTCCAGCCA 148
 QY 571 GCTGCCAGGGAACACCACTGCTCAGTGCAGAACCATTTACAGCTTCACTGTCGCCGAAA 630
 DB 147 GCTGCCAGGGAACACCACTGCTCAGTGCAGAACCATTTACAGCTTCACTGTCGCCGAAA 88
 QY 631 TACAGCAAGTTCTTAAGCCCACTGCTTCTTCTGAGAGTCCAGG 677
 DB 87 TACAGCAAGTTCTTAAGCCCACTGCTTCTTCTGAGAGTCCAGG 41

RESULT 15

ID AAF65522/C
 AC AAF65522 standard; cDNA; 382 BP.

XX AAF65522;

DT 09-APR-2001 (first entry)

DE Novel human polynucleotide, SEQ ID NO: 1278.

KM Human; cytosolic; gene therapy; colon cancer; prostate cancer;

XX breast cancer; lung cancer; cancer detection; 88.

OS Homo sapiens.

XX WO200102568-A2.

PD 11-JAN-2001.

PF 30-JUN-2000; 2000WO-US18374.

PR 02-JUL-1999; 98US-0142310.

PR 02-JUL-1999; 99US-0142311.

PA (CHIR) CHIRON CORP.

PA (HYSB-) HYSBQ INC.

XX Williams LT, Escobedo J, Innis MA, Garcia PD, Klinger J, Kassam A,

PI Reinhard C, Randazzo P, Kennedy GC, Pot D, Lamson G, Drmanac R,

PI Cirenjakov R, Drmanac S, Dickson M, Labat I, Leshkevitz D,

PI Kita D, Garcia V, Jones JW, Strache-Crain B,

DR WPI; 2001-091805/10.

XX Library of polynucleotides for diagnosing a cancerous state of a

PT mammalian cell and detecting cancer, particularly of the colon or

PT prostate, comprises 3351 human polynucleotide sequences -

XX Claim 9; Page 727; 1046pp; English.

CC The present sequence is one of 3351 sequences in a library of human
 CC polynucleotides. The library is used to detect differentially expressed
 CC genes correlated with a cancerous state of a mammalian cell and can
 CC detect colon, prostate, breast, and lung cancer. The library can be used
 CC to produce probes for detection of mRNA and to produce additional copies
 CC of the polynucleotides. The probes can be used for chromosome mapping of
 CC the polynucleotide and for detection of transcription levels. Ribozymes
 CC or antisense oligonucleotides can be generated. The polynucleotides and
 CC their gene products are used as genetic or biochemical markers (e.g. in
 CC blood or tissues) that will detect the earliest changes along the
 CC carcinogenesis pathway and/or monitor the efficacy of therapies and
 CC preventive interventions. The polynucleotides, polypeptides and
 CC antibodies against them can be used in pharmaceutical compositions to
 CC treat the cancers and proliferative disorders such as neoplasia,
 CC dysplasia and hyperplasia.

XX Sequence 382 BP; 77 A; 130 G; 98 T; 0 other;

Query Match

11.0%; Score 162.2; DB 22; Length 382;

Best Local Similarity 98.2%; Pred. No. 2.1e-32;
 Matches 164; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 511 AACAGAGCCCTATTTCAGTCACTCCCAATGCGAGCCAGTCCAGATCACTCTCCAGCCA 570
 DB 207 AACAGAGCCCTATTTCAGTCACTCCCAATGCGAGCCAGTCCAGATCACTCTCCAGCCA 148
 QY 571 GCTGCCAGGGAACACCACTGCTCAGTGCAGAACCATTTACAGCTTCACTGTCGCCGAAA 630
 DB 147 GCTGCCAGGGAACACCACTGCTCAGTGCAGAACCATTTACAGCTTCACTGTCGCCGAAA 88
 QY 631 TACAGCAAGTTCTTAAGCCCACTGCTTCTTCTGAGAGTCCAGG 677
 DB 87 TACAGCAAGTTCTTAAGCCCACTGCTTCTTCTGAGAGTCCAGG 41

Search completed: September 17, 2003, 18:50:47
 Job time : 292.676 secs